Clinical Trials Directory

Trials / Completed

CompletedNCT02231671

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of 14C-ALS-008176 in Healthy Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Alios Biopharma Inc. · Industry
Sex
Male
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to see how ALS-008176 is taken up, broken down, and removed from the body.

Conditions

Interventions

TypeNameDescription
DRUGALS-008176
DRUGALS-008112

Timeline

Start date
2014-08-31
Primary completion
2014-09-30
Completion
2014-11-30
First posted
2014-09-04
Last updated
2017-10-31

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02231671. Inclusion in this directory is not an endorsement.

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 (NCT02231671) · Clinical Trials Directory